IVD Market in the US

Price :
Published : Jun-2015
No. of Pages : 85

IVD Market in the US 2015-2019

The following companies are the key players in the IVD market in the US: Abbott Laboratories, bioMérieux, Danaher, Roche Diagnostics and Siemens Healthcare

Other Prominent Vendors in the market are: A. Menarini Diagnostics, ARKRAY, Affymetrix, Agilent Technologies, Alere, Axis-Shield, Bio-Rad Laboratories, Bruker BioSciences, Cepheid, Dako, DiaSorin, ELITech, Eiken Chemical, Fujirebio Diagnostics, GE Healthcare, Grifols, Horiba, Illumina, Instrumentation Laboratory, Johnson & Johnson, Luminex, Magellan Biosciences, Nanosphere, Nova Biomedical, Nova Century Scientific, PerkinElmer, Phadia, QIAGEN, Quidel, Quest Diagnostics, Randox Laboratories, Sysmex Hematology, Tosoh, Trinity Biotech and Werfen Life Group

Commenting on the report, an analyst said: "Disease management and individualized treatment can be enabled by diagnostic tests, which can provide real-time or rapid results. For instance, glycated hemoglobin and blood glucose monitoring tests for diabetes, cholesterol monitoring in lipid-lowering therapy, and blood level monitoring of antiretroviral drugs in HIV strains allow clinicians to obtain diagnostic information and reduce the likelihood of adverse events. These treatments can also be managed by real-time, customized approaches. Personalizing these treatments will enable better channeling of diagnostic information of the patient, and thereby communicate results directly to clinicians."

According to the report, the Healthcare Reform Act of 2010 aimed to increase accessibility and provide quality healthcare at affordable costs to all citizens. Since its initiation, there has been an increase in the number of citizens covered by insurance. According to the Congressional Budget Office, by 2015, almost 19 million US citizens will be covered by insurance as a result of PPACA. In addition, it introduced preventive services for women such as screening for cervical cancer and mammograms, which will be covered by health plans. The full-time employees of large companies also benefited because they were initially denied health insurance by their employers. These factors will give an impetus to the growth of the market.

Further, the report states that regulatory and reimbursement issues hinder the sales of IVD components, thereby hampering market growth.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Filed in: In Vitro Diagnostic, Medical Device
Publisher : Technavio